Annual Meeting Proxy Details Merger Equity Treatment and Significant Tax Receivable Agreement Waiver

summarizeSummary

Olaplex Holdings filed its definitive proxy statement for its annual meeting, detailing director elections, executive compensation, and auditor ratification. The filing also provided key financial specifics for the pending Henkel acquisition, including the treatment of equity awards and a significant waiver of Tax Receivable Agreement payments by major shareholders.

check_boxKey Events · Corporate Governance and Compliance · OLPX

• Annual Meeting Scheduled

  The 2026 Annual Meeting of Stockholders will be held virtually on July 9, 2026, to elect four Class II directors, approve executive compensation, and ratify Deloitte & Touche LLP as the independent auditor.

• Merger Equity Award Treatment Detailed

  Upon the closing of the Henkel acquisition, outstanding stock options will be cancelled for a cash payment equal to the excess of $2.06 over their exercise price, and outstanding Restricted Stock Units (RSUs) will be cancelled for a cash payment of $2.06 per share.

• Significant Tax Receivable Agreement (TRA) Waiver

  Major shareholders, including Advent Funds, have waived their rights to future payments under the Tax Receivable Agreement, which will automatically terminate upon the merger's effective time. This removes a significant future liability, as the company made a $12.1 million payment under the TRA in fiscal year 2025.

• Executive Compensation for Fiscal Year 2025

  CEO Amanda Baldwin's total compensation for fiscal year 2025 was $6,541,537, with $5,000,000 in RSU awards. The company achieved 103% of its target for annual cash bonuses based on net sales and adjusted EBITDA.

auto_awesomeAnalysis · OLPX · Industrial Applications And Services

This definitive proxy statement outlines the agenda for the upcoming annual meeting, but more importantly, it provides crucial financial details related to the pending acquisition by Henkel. The filing confirms how equity awards will be treated in the merger, with RSUs cashing out at $2.06 per share and in-the-money options at the difference between $2.06 and their exercise price. Furthermore, major shareholders, including Advent Funds, have waived their rights to future payments under the Tax Receivable Agreement (TRA), which will terminate upon the merger's close. This TRA waiver is a material positive development for the acquisition's financial terms, removing a significant future liability for the company.